Patents by Inventor Klaus Rudolf

Klaus Rudolf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210061761
    Abstract: The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)
    Type: Application
    Filed: August 26, 2020
    Publication date: March 4, 2021
    Inventors: Kai GERLACH, Christian EICKMEIER, Jan Magnus KRIEGL, Lothar KUSSMAUL, Klaus RUDOLF, Bernhard SCHMID
  • Patent number: 10675268
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: June 9, 2020
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Patent number: 10577336
    Abstract: The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: March 3, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rocco Mazzaferro, Marco Ferrara, Riccardo Giovannini, Iain Lingard, Klaus Rudolf
  • Publication number: 20190269650
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Application
    Filed: November 2, 2018
    Publication date: September 5, 2019
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Patent number: 10166214
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: January 1, 2019
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Publication number: 20180339971
    Abstract: The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.
    Type: Application
    Filed: July 30, 2018
    Publication date: November 29, 2018
    Inventors: Rocco MAZZAFERRO, Marco FERRARA, Riccardo GIOVANNINI, Iain LINGARD, Klaus RUDOLF
  • Patent number: 10071974
    Abstract: The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: September 11, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Rocco Mazzaferro, Marco Ferrara, Riccardo Giovannini, Iain Lingard, Klaus Rudolf
  • Publication number: 20180092880
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Application
    Filed: August 24, 2017
    Publication date: April 5, 2018
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Publication number: 20170320838
    Abstract: The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.
    Type: Application
    Filed: November 12, 2015
    Publication date: November 9, 2017
    Inventors: Rocco MAZZAFERRO, Marco FERRARA, Riccardo GIOVANNINI, Iain LINGARD, Klaus RUDOLF
  • Patent number: 9789082
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: October 17, 2017
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Publication number: 20170014381
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Application
    Filed: May 18, 2016
    Publication date: January 19, 2017
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doobs, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Publication number: 20160223268
    Abstract: The invention relates to a heat accumulator for storing thermal energy in at least one heat accumulator block, which heat accumulator has a removal device for removing stored thermal energy. For the uniform removal of energy from the accumulator, the heat accumulator block and the removal device according to the invention are separate from each other and can be moved in relation to each other. At least one heat-exchanger surface for transferring heat from a fluid or an electrical heating element into the heat accumulator block can be provided in the heat accumulator block. For the removal of thermal energy from the heat accumulator block, the removal device can have at least one evaporator surface for producing a phase change in a heat-transfer fluid.
    Type: Application
    Filed: September 4, 2014
    Publication date: August 4, 2016
    Applicant: JESS GmbH Energiespeichersysteme
    Inventors: Klaus Rudolf Quast, Peter Manfred Roessler
  • Patent number: 9371282
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: June 21, 2016
    Assignee: Centrexion Therapeutics Corporation
    Inventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
  • Patent number: 9346816
    Abstract: The present invention relates to compounds defined by formula I wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: May 24, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephan-Georg Mueller, Christopher John Brown, Alexander Heifetz, Bernd Nosse, Juergen Prestle, Natacha Prevost, Klaus Rudolf, Stefan Scheuerer, Marcus Schindler, Dirk Stenkamp, Leo Thomas, Heather Tye
  • Patent number: 9115093
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: August 25, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Gnamm, Thorsten Oost, Stefan Peters, Klaus Rudolf
  • Patent number: 8952014
    Abstract: The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: February 10, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Henri Doods, Annekatrin Heimann, Stephan Georg Mueller, Klaus Rudolf, Gerhard Schaenzle, Dirk Stenkamp
  • Patent number: 8937176
    Abstract: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: January 20, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Rudolf, Daniel Bischoff, Georg Dahmann, Matthias Grauert, Raimund Kuelzer
  • Publication number: 20140343065
    Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.
    Type: Application
    Filed: May 12, 2014
    Publication date: November 20, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Riccardo GIOVANNINI, Yunhai CUI, Henri DOODS, Marco FERRARA, Stefan JUST, Raimund KUELZER, Iain LINGARD, Rocco MAZZAFERRO, Klaus RUDOLF
  • Patent number: 8889677
    Abstract: This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: November 18, 2014
    Assignee: Boehringer Ingellheim International GmbH
    Inventors: Matthias Grauert, Daniel Bischoff, Georg Dahmann, Raimund Kuelzer, Klaus Rudolf
  • Patent number: RE47493
    Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: July 9, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Gnamm, Thorsten Oost, Stefan Peters, Klaus Rudolf